The therapeutic response to treatment with human growth hormone (GH(UK)) provided first by the Medical Research Council and now by the Department of Health and Social Security has been reported in some detail.1-2 The impression that this therapeutic regimen is generally satisfactory was recently challenged3 and it was alleged that treatment with GH(UK) causes disproportionate osseous maturation for height gain, with ultimate stunting. It is suggested that these effects are due to contaminating pituitary peptides, in particular gonadotropins, which are responsible for supposedly premature stimulation of gonadal function. Earlier accounts of treatment with GH(UK)2 and other therapeutic GH preparations4-did not report inappropriate skeletal maturation as a result of treatment, but in view of the serious implications of this recent communication we have studied in detail the records of 201 children treated with GH(UK), particularly their growth in height and advancement in skeletal maturity.
Patients and methods
The 201 patients comprised all those who have been treated for at least one year with GH(UK) since 1959, for whom serial records of height growth and bone age were available. Many of them attended the growth clinic at The Hospital for Sick Children, London, and a few attended other growth centres in the UK. The 'years'/year. Fig. 2 shows bone age velocity during the first 0.^year of treatment plotted against bone age at the beginning of treatment in the three diagnostic groups. There is no association except that in the S *, ., craniopharyngioma groups there was a tendency 12 14 16 towards low velocity in those patients with bone ages of 10 or more at the start of treatment. The mean overall bone age velocity in each diagnostic group during the first year of treatment (Table 2) was similar to the mean velocity calculated over the total period of treatment with GH, being 1 * 11 and 1 00 'years'/year for the isolated GH and panhypopituitary groups, and O * 56 'years'/year in craniopharyngioma.
Bone age velocity in the first year of treatment of patients with isolated GH-deficiency was analysed to see if there was an association with degree of retardation of osseous development-that is chronological age minus bone age (Fig. 3) . There is no significant relation between these variables (n = 103, r = 022, P>005).
Height. Height gained while on treatment with GH was analysed with reference to bone age so that the hypothesis that GH causes disproportionate osseous maturation for height gain could be tested. The mean height SD score for bone age in the three diagnostic groups is shown in relation to the number of years of continuous treatment with GH (Table 3 ). In the largest group, isolated GH deficiency, the score became progressively less negative as the duration of treatment increased, indicating that the children gained more in height than in osseous maturation as a result of GH therapy. Patients with craniopharyngioma showed a pronounced 'catch up' in height for bone age in the first 5 years of treatment.
In the smallest group, those with panhypopituitarism, (Fig. 4) . In Fig. 5 Growth in height in relation to skeletal development can be analysed by the calculation of height SD score for bone age. The demonstration that height SD score for bone age improved as treatment with GH continued in the patients with isolated GH deficiency, clearly refutes the idea that GH(UK) causes inappropriate osseous maturation for height gained. The figure showing the response of individual patients treated for 6 years demonstrates the danger of drawing conclusions from a small sample. In 2 patients there was a fall, in 3 no change, and in 10 a rise in height SD score for bone age. The results in craniopharyngioma were similar to those in isolated GH deficiency but the numbers were fewer. In panhypopituitarism no significant change in height SD score was observed, indicating parallel and appropriate response to treatment in both height and skeletal maturation.
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